Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.

View in: PubMed

subject areas

Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone
Female
Humans
Imides
Male
Middle Aged
Multiple Myeloma
Neoplasm, Residual
Proteasome Inhibitors

authors with profiles

Theodore Karrison
Benjamin Derman
Andrzej Jakubowiak
Sandeep Gurbuxani
Sunil Narula
David L. Grinblatt
Shayan Rayani